≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Atrioventricular septal defect

EFO Endpoint Browser PheWeb

Q17_AVSD

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q21.2
  • Hospital discharge: ICD-9 — 7456[B-C]|7458X
  • Hospital discharge: excluded ICD-10 — Q90|Q91|Q92|Q93|Q96|Q8780|Q8781|Q8782|Q8783|Q8784|Q8786|Q8788|Q85|Q796|Q874|Q875
  • Hospital discharge: excluded ICD-9 — 758|7595|75683
  • Cause of death: ICD-10 — Q21.2
  • Cause of death: ICD-9 — 7456[B-C]|7458X
  • Cause of death: excluded ICD-10 — Q90|Q91|Q92|Q93|Q96|Q8780|Q8781|Q8782|Q8783|Q8784|Q8786|Q8788|Q85|Q796|Q874|Q875
  • Cause of death: excluded ICD-9 — 758|7595|75683

2 out of 7 registries used, show all original rules.

152

4. Check minimum number of events

None

152

5. Include endpoints

None

152

6. Filter based on genotype QC (FinnGen only)

143

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF7

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2000 1168 826
Only index persons 1460 841 619
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.02
Only index persons 0.03 0.03 0.02
Median age at first event (years)
Whole population 4.19 4.72 3.16
Only index persons 8.98 10.27 7.24

-FinnGen-

Key figures

All Female Male
Number of individuals 143 87 56
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 32.39 30.41 35.47

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
152
Matched controls
1520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
FM1BE
NOMESCO Finland
Cardiac ultrasound examination through oesophagus
42.2
112.7
79
38
Q21.10
ICD-10 Finland
Persistent ostium secundum
73.5
104.4
59
13
Q21.20
ICD-10 Finland
Atrial septal defect of primum type
+∞
72.9
64
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
29.9
71.0
52
26
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
32.9
68.9
48
21
Q21.21
ICD-10 Finland
Atrioventricular duct
+∞
64.2
57
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
12.2
54.0
77
118
XF404
NOMESCO Finland
Ambulatory ECG
15.5
49.9
51
48
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
9.7
45.3
89
194
B01AA03
ATC
warfarin; systemic
11.1
42.1
56
76
I34.09
ICD-10 Finland
Mitral (valve) insufficiency
15.9
34.2
32
25
Q21.29
ICD-10 Finland
Atrioventricular septal defect UNS
+∞
33.6
31
*
Q21.19
ICD-10 Finland
Atrial septal defect NOS
193.0
30.9
31
*
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
9.1
30.8
45
67
C01AA05
ATC
digoxin; systemic
33.3
29.3
38
15
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.7
27.7
59
131
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
170.2
27.6
28
*
C03CA01
ATC
furosemide; systemic
6.3
27.1
66
166
WX872
NOMESCO Finland
Intensive care
27.3
26.3
36
17
XF400
NOMESCO Finland
ECG with 12 standard connections
6.2
24.7
57
135
XF620
NOMESCO Finland
Examination of circulation with color method
148.4
24.4
25
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
6.0
23.6
55
131
XF402
NOMESCO Finland
ECG with work load test
8.5
22.6
33
48
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.3
22.4
102
421
I48
ICD-10 Finland
Atrial fibrillation and flutter
6.7
22.3
43
85
FFC22
NOMESCO Finland
Percutaneous transluminal closure of ostium secundum type ASD
89.4
21.3
23
*
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
5.9
21.0
48
111
TPH04
NOMESCO Finland
Cathetrisation of vein
5.2
20.8
59
165
Q21.11
ICD-10 Finland
Paten or persistent foramen ovale
29.5
20.4
27
11
Q21.2
ICD-10 Finland
Atrioventricular septal defect
+∞
20.3
19
*
I50.9
ICD-10 Finland
Heart failure, unspecified
6.5
17.7
33
62
ZXE30
NOMESCO Finland
More than five and less than seven hours
8.4
17.1
24
33
31
HP
Congenital heart failure surgery
101.4
17.0
18
*
Q21.00
ICD-10 Finland
Multiple ventricular septal defect
53.9
16.4
19
*
TFP20
NOMESCO Finland
Cardiodefibrillation
8.0
16.2
24
35
207
Kela drug reimbursment
Chronic arrhythmias
5.9
16.1
33
68
7456C
ICD-9 Finland
Bulbus cordis anomalies and anomalies of cardiac septal closure, Endocardial cushion defects[ASD CANALIS ATRIOVENTRICULARIS COMMUNIS]
+∞
15.9
15
*
TPH07
NOMESCO Finland
Cathetrisation of artery
5.4
15.7
36
82
C03DA01
ATC
spironolactone; oral
5.5
15.4
35
79
FM1DG
NOMESCO Finland
Very extensive MRI examination of heart with high intesity magnet
24.1
15.1
21
10
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.4
15.1
28
52
WX704
NOMESCO Finland
Intubation
6.1
14.8
29
57
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
13.4
14.4
25
22
FFC00
NOMESCO Finland
Suture of ostium secundum type ASD
59.2
14.1
16
*
I34.00
ICD-10 Finland
Mitral (valve) incompetence NOS or of specified cause, except rheumatic
37.9
13.8
17
5
Q90.9
ICD-10 Finland
Down syndrome, unspecified
+∞
13.7
13
*
Q21.09
ICD-10 Finland
Ventricular septal defect NOS
44.3
13.4
16
*
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
6.6
13.2
23
40
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
14.1
13.1
22
18
Q90.0
ICD-10 Finland
Trisomy 21, meiotic nondisjunction
141.2
12.6
13
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.5
12.4
64
263
WX725
NOMESCO Finland
Noninvasive ventilation
6.4
12.3
22
39
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
23.7
12.3
17
8
TFB00
NOMESCO Finland
Cathetrisation of pulmonal artery
51.0
12.1
14
*
WX892
NOMESCO Finland
Monitored bed care
5.3
12.0
27
60
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
5.8
11.9
24
48
WX882
NOMESCO Finland
High dependency care
6.1
11.7
22
41
ZXE20
NOMESCO Finland
More than three and less than five hours
4.3
11.7
35
98
7455A
ICD-9 Finland
Bulbus cordis anomalies and anomalies of cardiac septal closure, Ostium secundum type atrial septal defect
+∞
11.6
11
*
74646
ICD-8 Finland
Congenital anomalies of heart, Defectus septi atriorum, ostium primum
+∞
11.6
11
*
Z2221
NOMESCO Finland
Medical doctor
3.3
11.2
66
290
ZXD10
NOMESCO Finland
Scheduled procedure
3.2
11.1
80
396
Q21.08
ICD-10 Finland
Other specifed ventricular septal defect
23.6
10.9
15
7
ZXE40
NOMESCO Finland
More than seven and less than nine hours
15.8
10.8
17
12
XA800
NOMESCO Finland
Neuropsychological investigation
5.3
10.1
22
47
62
HP
Catheterization and pressure measurement of the right side of the heart
58.9
9.8
11
*
AN1
HP
Coronary angiography
5.5
9.6
20
41
Q20.48
ICD-10 Finland
Single ventricle
106.4
9.5
10
*
XFE00
NOMESCO Finland
Epicardial ultrasonography
23.5
9.5
13
6
Q21.28
ICD-10 Finland
Atrioventricular septal defect
+∞
9.5
9
*
FFC42
NOMESCO Finland
Percutaneous closure of patent foramen ovale
+∞
9.5
9
*
7580A
ICD-9 Finland
Chromosomal anomalies, Down's syndrome
+∞
9.5
9
*
AF1
HP
Surgery of congenital heart defect
+∞
9.5
9
*
FFD20
NOMESCO Finland
Closure of atrio-ventricular septal defect using patch
+∞
9.5
9
*
K78
ICPC
Atrial fibrillation/flutter
8.4
9.3
20
27
FN1BC
NOMESCO Finland
Extensive angiography of hear and/or coronary arteries
9.1
8.9
18
22
61
HP
Catheterization and pressure measurement of the left side of the heart
21.5
8.6
12
6
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
29.4
8.6
11
*
Q21.18
ICD-10 Finland
Other spedified atrial septal defect
+∞
8.4
8
*
7456B
ICD-9 Finland
Bulbus cordis anomalies and anomalies of cardiac septal closure, Endocardial cushion defects[DEFECTUS SEPTI ATRIORUM, OSTII PRIMII]
+∞
8.4
8
*
I44.2
ICD-10 Finland
Atrioventricular block, complete
15.6
8.4
13
9
XF622
NOMESCO Finland
Measurement of minute volume of heart
35.4
8.2
10
*
FM2CE, ,
NOMESCO Finland
8.6
8.1
17
22
B01AC04
ATC
clopidogrel; oral
3.9
8.1
26
76
C07AB07
ATC
bisoprolol; oral
2.7
8.1
68
352
I50.0
ICD-10 Finland
Congestive heart failure
7.4
7.9
18
27
C01BD01
ATC
amiodarone; systemic
16.1
7.9
12
8
C07AA07
ATC
sotalol; systemic
12.8
7.7
13
11
Q25.0
ICD-10 Finland
Patent ductus arteriosus
26.5
7.7
10
*
ZX120
NOMESCO Finland
Intravenous
3.8
7.6
25
74
FPE20
NOMESCO Finland
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
14.3
7.5
12
9
FM1CG
NOMESCO Finland
Extensive examination of hear with high intensity magnet
84.0
7.5
8
*
C09AA02
ATC
enalapril; systemic
3.4
7.5
30
102
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
7.4
46
202
74647
ICD-8 Finland
Congenital anomalies of heart, Ostium atrioventriculare commune
+∞
7.3
7
*
74663
ICD-8 Finland
Congenital anomalies of heart, Stenosis valvulae pulmonalis
+∞
7.3
7
*
Q21.1
ICD-10 Finland
Atrial septal defect
+∞
7.3
7
*
ZXD05
NOMESCO Finland
Urgent procedure
2.6
7.3
58
288
G04BE03
ATC
sildenafil; oral
31.7
7.2
9
*
J96.1
ICD-10 Finland
Chronic respiratory failure
31.7
7.2
9
*
WX720
NOMESCO Finland
Own respiration
7.6
7.2
16
23
XF600
NOMESCO Finland
Bloodpressure measurement
4.0
7.2
22
62
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
7.2
43
185
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
7.1
64
338
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.7
7.0
24
73
I49.5
ICD-10 Finland
Sick sinus syndrome
11.7
6.9
12
11
Q25.1
ICD-10 Finland
Coarctation of aorta
42.0
6.8
8
*
Q21.9
ICD-10 Finland
Congenital malformation of cardiac septum, unspecified
42.0
6.8
8
*
I48.2
ICD-10 Finland
Chronic atrial fibrillation
13.1
6.7
11
9
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.6
6.7
49
233
AA1AD
NOMESCO Finland
CT of head and brain
2.7
6.7
45
205
XF640, ,
NOMESCO Finland
10.7
6.7
12
12
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.4
6.5
17
42
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.4
6.5
26
88
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.7
6.5
44
201
UGC02
NOMESCO Finland
Rigid bronchoscopy
72.8
6.5
7
*
Q21.30
ICD-10 Finland
Tetralogy of Fallot
72.8
6.5
7
*
AP2
HP
Catheterization of the right side of the heart
72.8
6.5
7
*
I47.2
ICD-10 Finland
Ventricular tachycardia
11.7
6.4
11
10
TFC99
NOMESCO Finland
Catheterisation of heart with other procedure
19.0
6.3
9
5
I83.0
ICD-10 Finland
Varicose veins of lower extremities with ulcer
19.0
6.3
9
5
Q22.1
ICD-10 Finland
Congenital pulmonary valve stenosis
27.9
6.3
8
*
I48.4
ICD-10 Finland
Atypical atrial flutter
+∞
6.3
6
*
I37.1
ICD-10 Finland
Pulmonary valve insufficiency
+∞
6.3
6
*
AP3
HP
Catheterization of the right and left side of the heart
+∞
6.3
6
*
74642
ICD-8 Finland
Congenital anomalies of heart, Defectus septi atriorum, ostium secundum
+∞
6.3
6
*
7454A
ICD-9 Finland
Bulbus cordis anomalies and anomalies of cardiac septal closure, Ventricular septal defect[DEFECTUS SEPTI VENTRICULORUM NUD]
+∞
6.3
6
*
Q20.3
ICD-10 Finland
Discordant ventriculoarterial connection
+∞
6.3
6
*
74639
ICD-8 Finland
Congenital anomalies of heart, Defectus septi ventriculorum
+∞
6.3
6
*
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
6.3
6
*
I48.1
ICD-10 Finland
Persistent atrial fibrillation
9.2
6.2
12
14
K84
ICPC
Heart disease other
13.3
6.2
10
8

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Cardiology
6 [38004451]
1.9e+00
3.1e+00
—
1.0e+50
3.7e+00
3.9e+00
2.6e+00
cases:26.36%
controls:5.24%
cases:34.23%
controls:2.19%
—
—
cases:45.05%
controls:0.00%
cases:20.18%
controls:0.64%
cases:48.62%
controls:1.84%
cases:46.53%
controls:5.89%
29
57
81
1030
38
24
73
1073
—
50
0
61
1097
22
7
87
1090
53
20
56
1069
47
58
54
927
warfarin; oral, parenteral
B01AA03 [21600965]
2.4e+00
2.6e+00
—
—
—
3.1e+00
2.8e+00
cases:15.45%
controls:1.66%
cases:15.32%
controls:1.28%
—
—
—
—
—
—
cases:26.61%
controls:1.56%
cases:26.73%
controls:2.13%
17
18
93
1069
17
14
94
1083
—
—
—
29
17
80
1072
27
21
74
964
Atrial fibrillation and flutter
I48 [45596206]
2.3e+00
3.0e+00
—
1.0e+50
—
2.8e+00
2.2e+00
cases:14.55%
controls:1.66%
cases:16.22%
controls:0.91%
—
—
cases:10.81%
controls:0.00%
—
—
cases:17.43%
controls:1.29%
cases:19.80%
controls:2.64%
16
18
94
1069
18
10
93
1087
—
12
0
99
1097
—
19
14
90
1075
20
26
81
959
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.8e+00
2.7e+00
—
1.0e+50
—
3.6e+00
2.1e+00
cases:8.18%
controls:1.47%
cases:9.01%
controls:0.64%
—
—
cases:4.50%
controls:0.00%
—
—
cases:16.51%
controls:0.55%
cases:18.81%
controls:2.84%
9
16
101
1071
10
7
101
1090
—
5
0
106
1097
—
18
6
91
1083
19
28
82
957
clopidogrel; oral
B01AC04 [21600989]
—
2.5e+00
—
—
2.9e+00
2.6e+00
1.9e+00
—
—
cases:10.81%
controls:1.00%
—
—
—
—
cases:9.17%
controls:0.55%
cases:11.01%
controls:0.92%
cases:7.92%
controls:1.32%
—
12
11
99
1086
—
—
10
6
99
1091
12
10
97
1079
8
13
93
972
Standard cardiac ultrasound examination
FM1AE [2001303278]
2.5e+00
3.3e+00
—
1.0e+50
1.0e+50
—
3.1e+00
cases:10.91%
controls:1.01%
cases:10.81%
controls:0.46%
—
—
cases:17.12%
controls:0.00%
cases:7.34%
controls:0.00%
—
—
cases:24.75%
controls:1.42%
12
11
98
1076
12
5
99
1092
—
19
0
92
1097
8
0
101
1097
—
25
14
76
971
furosemide; oral, parenteral
C03CA01 [21601518]
8.4e-01
1.8e+00
—
—
2.7e+00
2.2e+00
1.7e+00
cases:6.36%
controls:2.85%
cases:10.81%
controls:1.91%
—
—
—
—
cases:6.42%
controls:0.46%
cases:17.43%
controls:2.20%
cases:20.79%
controls:4.47%
7
31
103
1056
12
21
99
1076
—
—
7
5
102
1092
19
24
90
1065
21
44
80
941
Internal Medicine
11 [38004456]
8.9e-01
1.8e+00
1.5e+00
—
3.0e+00
1.6e+00
9.3e-01
cases:30.00%
controls:15.00%
cases:29.73%
controls:6.56%
cases:5.41%
controls:1.28%
—
—
cases:15.60%
controls:0.91%
cases:27.52%
controls:7.16%
cases:35.64%
controls:17.87%
33
163
77
924
33
72
78
1025
6
14
105
1083
—
17
10
92
1087
30
78
79
1011
36
176
65
809
INR in Blood by Coagulation assay
34714-6 [3032080]
1.1e+00
1.9e+00
3.3e+00
1.0e+50
—
1.4e+00
8.8e-01
cases:12.73%
controls:4.69%
cases:17.12%
controls:3.10%
cases:10.81%
controls:0.46%
cases:4.50%
controls:0.00%
—
—
cases:10.09%
controls:2.66%
cases:12.87%
controls:5.79%
14
51
96
1036
19
34
92
1063
12
5
99
1092
5
0
106
1097
—
11
29
98
1060
13
57
88
928
bisoprolol; oral
C07AB07 [21601689]
1.3e+00
1.3e+00
1.3e+00
—
1.5e+00
1.7e+00
1.6e+00
cases:23.64%
controls:7.54%
cases:21.62%
controls:7.02%
cases:8.11%
controls:2.28%
—
—
cases:10.09%
controls:2.37%
cases:29.36%
controls:7.16%
cases:38.61%
controls:10.96%
26
82
84
1005
24
77
87
1020
9
25
102
1072
—
11
26
98
1071
32
78
77
1011
39
108
62
877
Emergency Room Visit
ER [9203]
5.2e-01
1.8e+00
2.2e+00
1.0e+50
2.1e+00
1.1e+00
3.4e-01
cases:37.27%
controls:26.03%
cases:35.14%
controls:8.11%
cases:7.21%
controls:0.82%
cases:4.50%
controls:0.00%
cases:7.34%
controls:0.91%
cases:22.02%
controls:8.36%
cases:32.67%
controls:25.58%
41
283
69
804
39
89
72
1008
8
9
103
1088
5
0
106
1097
8
10
101
1087
24
91
85
998
33
252
68
733
12 lead EKG panel
34534-8 [3044889]
5.5e-01
1.3e+00
1.5e+00
—
3.3e+00
1.2e+00
9.3e-01
cases:16.36%
controls:10.12%
cases:17.12%
controls:5.10%
cases:4.50%
controls:1.00%
—
—
cases:11.01%
controls:0.46%
cases:14.68%
controls:5.14%
cases:23.76%
controls:10.96%
18
110
92
977
19
56
92
1041
5
11
106
1086
—
12
5
97
1092
16
56
93
1033
24
108
77
877
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
1.4e+00
2.6e+00
—
—
—
2.3e+00
1.8e+00
cases:7.27%
controls:1.93%
cases:12.61%
controls:1.09%
—
—
—
—
—
—
cases:9.17%
controls:1.01%
cases:8.91%
controls:1.52%
8
21
102
1066
14
12
97
1085
—
—
—
10
11
99
1078
9
15
92
970
Outpatient Hospital
22 [8756]
5.6e-01
1.3e+00
—
—
2.5e+00
1.6e+00
8.1e-01
cases:30.91%
controls:20.33%
cases:18.92%
controls:5.74%
—
—
—
—
cases:8.26%
controls:0.73%
cases:21.10%
controls:5.23%
cases:30.69%
controls:16.45%
34
221
76
866
21
63
90
1034
—
—
9
8
100
1089
23
57
86
1032
31
162
70
823
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
3.8e-01
1.1e+00
2.0e+00
—
2.2e+00
9.2e-01
4.3e-01
cases:20.00%
controls:14.63%
cases:25.23%
controls:10.30%
cases:13.51%
controls:2.10%
—
—
cases:17.43%
controls:2.37%
cases:24.77%
controls:11.57%
cases:29.70%
controls:21.62%
22
159
88
928
28
113
83
984
15
23
96
1074
—
19
26
90
1071
27
126
82
963
30
213
71
772
CBC panel - Blood by Automated count
58410-2 [40761511]
2.0e-01
1.0e+00
1.7e+00
—
2.4e+00
9.1e-01
4.3e-01
cases:23.64%
controls:20.15%
cases:24.32%
controls:10.12%
cases:11.71%
controls:2.28%
—
—
cases:18.35%
controls:2.01%
cases:25.69%
controls:12.21%
cases:31.68%
controls:23.25%
26
219
84
868
27
111
84
986
13
25
98
1072
—
20
22
89
1075
28
133
81
956
32
229
69
756
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.3e-01
1.0e+00
1.7e+00
—
2.3e+00
9.0e-01
4.9e-01
cases:20.00%
controls:17.94%
cases:25.23%
controls:10.94%
cases:13.51%
controls:2.64%
—
—
cases:18.35%
controls:2.28%
cases:24.77%
controls:11.85%
cases:32.67%
controls:22.94%
22
195
88
892
28
120
83
977
15
29
96
1068
—
20
25
89
1072
27
129
82
960
33
226
68
759
Laboratory Visit
OMOP4822461 [32036]
1.1e-02
4.2e-01
1.5e+00
2.6e+00
1.6e+00
3.2e-01
2.4e-01
cases:27.27%
controls:27.05%
cases:30.63%
controls:22.52%
cases:20.72%
controls:5.47%
cases:7.21%
controls:0.55%
cases:23.85%
controls:6.02%
cases:32.11%
controls:25.62%
cases:40.59%
controls:35.03%
30
294
80
793
34
247
77
850
23
60
88
1037
8
6
103
1091
26
66
83
1031
35
279
74
810
41
345
60
640
Outpatient Visit
OP [9202]
4.6e-01
9.7e-01
-3.9e-02
—
1.7e+00
1.3e+00
1.7e+00
cases:68.18%
controls:57.41%
cases:60.36%
controls:36.65%
cases:7.21%
controls:7.47%
—
—
cases:31.19%
controls:7.75%
cases:67.89%
controls:37.10%
cases:91.09%
controls:64.67%
75
624
35
463
67
402
44
695
8
82
103
1015
—
34
85
75
1012
74
404
35
685
92
637
9
348
Cathetrisation of vein
TPH04 [2001309597]
1.5e+00
—
—
—
1.0e+50
2.3e+00
1.7e+00
cases:8.18%
controls:1.93%
—
—
—
—
—
—
cases:10.09%
controls:0.00%
cases:5.50%
controls:0.55%
cases:8.91%
controls:1.83%
9
21
101
1066
—
—
—
11
0
98
1097
6
6
103
1083
9
18
92
967
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.5e-01
8.8e-01
2.1e+00
—
2.3e+00
7.1e-01
4.2e-01
cases:20.00%
controls:17.76%
cases:24.32%
controls:11.76%
cases:14.41%
controls:2.01%
—
—
cases:17.43%
controls:2.01%
cases:23.85%
controls:13.31%
cases:32.67%
controls:24.16%
22
193
88
894
27
129
84
968
16
22
95
1075
—
19
22
90
1075
26
145
83
944
33
238
68
747
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.4e-01
8.7e-01
2.1e+00
—
2.3e+00
7.2e-01
4.1e-01
cases:20.00%
controls:17.85%
cases:24.32%
controls:11.85%
cases:14.41%
controls:2.01%
—
—
cases:17.43%
controls:2.01%
cases:23.85%
controls:13.22%
cases:32.67%
controls:24.37%
22
194
88
893
27
130
84
967
16
22
95
1075
—
19
22
90
1075
26
144
83
945
33
240
68
745
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
2.7e+00
1.0e+50
—
—
2.3e+00
—
—
—
cases:9.91%
controls:0.73%
cases:4.50%
controls:0.00%
—
—
—
—
cases:4.59%
controls:0.46%
—
—
—
11
8
100
1089
5
0
106
1097
—
—
5
5
104
1084
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-7.9e-02
9.9e-01
1.5e+00
—
2.3e+00
4.9e-01
3.1e-01
cases:16.36%
controls:17.48%
cases:23.42%
controls:10.21%
cases:9.01%
controls:2.10%
—
—
cases:17.43%
controls:2.01%
cases:18.35%
controls:12.12%
cases:28.71%
controls:22.74%
18
190
92
897
26
112
85
985
10
23
101
1074
—
19
22
90
1075
20
132
89
957
29
224
72
761
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.3e-02
8.8e-01
2.0e+00
—
1.9e+00
6.2e-01
4.0e-01
cases:20.91%
controls:20.70%
cases:27.03%
controls:13.31%
cases:15.32%
controls:2.37%
—
—
cases:17.43%
controls:3.01%
cases:26.61%
controls:16.35%
cases:35.64%
controls:27.11%
23
225
87
862
30
146
81
951
17
26
94
1071
—
19
33
90
1064
29
178
80
911
36
267
65
718
Ambulatory ECG
XF404 [2001303370]
2.2e+00
1.0e+50
—
—
—
—
2.3e+00
cases:6.36%
controls:0.74%
cases:7.21%
controls:0.00%
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.81%
7
8
103
1079
8
0
103
1097
—
—
—
—
8
8
93
977
Inpatient Hospital
21 [8717]
6.4e-01
1.4e+00
1.6e+00
—
1.7e+00
1.4e+00
4.7e-01
cases:40.00%
controls:25.94%
cases:27.93%
controls:8.66%
cases:4.50%
controls:0.91%
—
—
cases:9.17%
controls:1.73%
cases:24.77%
controls:7.81%
cases:29.70%
controls:20.91%
44
282
66
805
31
95
80
1002
5
10
106
1087
—
10
19
99
1078
27
85
82
1004
30
206
71
779
amoxicillin; oral, parenteral
J01CA04 [21602823]
7.0e-01
5.8e-01
-1.0e+50
—
2.1e+00
1.1e+00
1.2e+00
cases:36.36%
controls:22.08%
cases:12.61%
controls:7.47%
cases:0.00%
controls:0.64%
—
—
cases:5.50%
controls:0.73%
cases:13.76%
controls:4.96%
cases:46.53%
controls:21.32%
40
240
70
847
14
82
97
1015
0
7
111
1090
—
6
8
103
1089
15
54
94
1035
47
210
54
775
Scheduled procedure
ZXD10 [2001311387]
1.4e-01
1.5e+00
—
1.0e+50
—
2.9e+00
1.4e+00
cases:4.55%
controls:3.96%
cases:6.31%
controls:1.55%
—
—
cases:6.31%
controls:0.00%
—
—
cases:11.01%
controls:0.64%
cases:10.89%
controls:2.94%
5
43
105
1044
7
17
104
1080
—
7
0
104
1097
—
12
7
97
1082
11
29
90
956
Neurology
13 [38004458]
4.6e-01
2.2e+00
2.0e+00
—
—
8.3e-01
8.9e-01
cases:8.18%
controls:5.34%
cases:15.32%
controls:2.01%
cases:5.41%
controls:0.73%
—
—
—
—
cases:5.50%
controls:2.48%
cases:15.84%
controls:7.21%
9
58
101
1029
17
22
94
1075
6
8
105
1089
—
—
6
27
103
1062
16
71
85
914
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
5.2e-02
1.4e+00
—
—
2.8e+00
9.5e-01
-3.0e-01
cases:4.55%
controls:4.32%
cases:9.91%
controls:2.73%
—
—
—
—
cases:7.34%
controls:0.46%
cases:5.50%
controls:2.20%
cases:4.95%
controls:6.60%
5
47
105
1040
11
30
100
1067
—
—
8
5
101
1092
6
24
103
1065
5
65
96
920
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.7e-01
1.5e+00
2.6e+00
—
—
1.2e+00
5.6e-01
cases:8.18%
controls:6.35%
cases:15.32%
controls:3.74%
cases:7.21%
controls:0.55%
—
—
—
—
cases:9.17%
controls:2.94%
cases:13.86%
controls:8.43%
9
69
101
1018
17
41
94
1056
8
6
103
1091
—
—
10
32
99
1057
14
83
87
902
Case Management Agency
251B00000X [38004193]
2.4e-01
1.5e-01
8.6e-01
3.3e+00
6.9e-01
3.1e-01
2.7e-01
cases:46.36%
controls:40.48%
cases:38.74%
controls:35.19%
cases:26.13%
controls:13.04%
cases:26.13%
controls:1.28%
cases:26.61%
controls:15.41%
cases:46.79%
controls:39.12%
cases:61.39%
controls:54.72%
51
440
59
647
43
386
68
711
29
143
82
954
29
14
82
1083
29
169
80
928
51
426
58
663
62
539
39
446
Thorax X-ray examination
GD1AA [2001303617]
8.6e-01
1.9e+00
—
—
—
2.2e+00
9.8e-01
cases:9.09%
controls:4.05%
cases:8.11%
controls:1.28%
—
—
—
—
—
—
cases:11.01%
controls:1.38%
cases:13.86%
controls:5.69%
10
44
100
1043
9
14
102
1083
—
—
—
12
15
97
1074
14
56
87
929
Medical doctor
Z2221 [2001311556]
9.1e-01
1.7e+00
—
1.0e+50
—
2.2e+00
1.7e+00
cases:6.36%
controls:2.67%
cases:5.41%
controls:1.00%
—
—
cases:5.41%
controls:0.00%
—
—
cases:6.42%
controls:0.73%
cases:13.86%
controls:2.84%
7
29
103
1058
6
11
105
1086
—
6
0
105
1097
—
7
8
102
1081
14
28
87
957
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
-5.5e-02
1.1e+00
2.6e+00
—
-1.0e+50
3.6e-01
2.1e-01
cases:15.45%
controls:16.19%
cases:18.02%
controls:6.84%
cases:7.21%
controls:0.55%
—
—
cases:0.00%
controls:0.91%
cases:11.93%
controls:8.63%
cases:22.77%
controls:19.29%
17
176
93
911
20
75
91
1022
8
6
103
1091
—
0
10
109
1087
13
94
96
995
23
190
78
795
spironolactone; oral
C03DA01 [21601534]
—
2.0e+00
-1.0e+50
—
—
1.8e+00
1.8e+00
—
—
cases:4.50%
controls:0.64%
cases:0.00%
controls:0.46%
—
—
—
—
cases:6.42%
controls:1.10%
cases:6.93%
controls:1.22%
—
5
7
106
1090
0
5
111
1092
—
—
7
12
102
1077
7
12
94
973
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
4.7e-03
6.5e-01
1.6e+00
—
1.9e+00
5.4e-01
2.6e-01
cases:23.64%
controls:23.55%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.37%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:36.63%
controls:30.76%
26
256
84
831
30
177
81
920
16
37
95
1060
—
20
37
89
1060
30
198
79
891
37
303
64
682
Platelets [#/volume] in Blood
26515-7 [3007461]
1.5e-02
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
2.6e-01
cases:23.64%
controls:23.37%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.09%
cases:36.63%
controls:30.76%
26
254
84
833
30
177
81
920
16
38
95
1059
—
20
37
89
1060
30
197
79
892
37
303
64
682
MCH [Entitic mass]
28539-5 [3035941]
9.8e-03
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
2.2e-01
cases:23.64%
controls:23.46%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:35.64%
controls:30.76%
26
255
84
832
30
177
81
920
16
38
95
1059
—
20
37
89
1060
30
198
79
891
36
303
65
682
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
4.7e-03
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
2.6e-01
cases:23.64%
controls:23.55%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:36.63%
controls:30.76%
26
256
84
831
30
177
81
920
16
38
95
1059
—
20
37
89
1060
30
198
79
891
37
303
64
682
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-3.7e-04
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
3.1e-01
cases:23.64%
controls:23.64%
cases:27.03%
controls:16.23%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:37.62%
controls:30.76%
26
257
84
830
30
178
81
919
16
38
95
1059
—
20
37
89
1060
30
198
79
891
38
303
63
682
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
4.7e-03
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
2.2e-01
cases:23.64%
controls:23.55%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:35.64%
controls:30.76%
26
256
84
831
30
177
81
920
16
38
95
1059
—
20
37
89
1060
30
198
79
891
36
303
65
682
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
4.7e-03
6.5e-01
1.5e+00
—
1.9e+00
5.4e-01
2.6e-01
cases:23.64%
controls:23.55%
cases:27.03%
controls:16.13%
cases:14.41%
controls:3.46%
—
—
cases:18.35%
controls:3.37%
cases:27.52%
controls:18.18%
cases:36.63%
controls:30.76%
26
256
84
831
30
177
81
920
16
38
95
1059
—
20
37
89
1060
30
198
79
891
37
303
64
682
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-1.2e-01
9.9e-01
2.4e+00
—
-1.0e+50
5.5e-01
2.3e-01
cases:15.45%
controls:17.02%
cases:19.82%
controls:8.39%
cases:7.21%
controls:0.73%
—
—
cases:0.00%
controls:1.00%
cases:16.51%
controls:10.28%
cases:26.73%
controls:22.44%
17
185
93
902
22
92
89
1005
8
8
103
1089
—
0
11
109
1086
18
112
91
977
27
221
74
764
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
-1.5e-01
9.7e-01
2.2e+00
—
-1.0e+50
4.9e-01
2.9e-01
cases:15.45%
controls:17.48%
cases:19.82%
controls:8.57%
cases:7.21%
controls:0.82%
—
—
cases:0.00%
controls:1.09%
cases:16.51%
controls:10.84%
cases:27.72%
controls:22.34%
17
190
93
897
22
94
89
1003
8
9
103
1088
—
0
12
109
1085
18
118
91
971
28
220
73
765
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
1.1e-01
9.9e-01
1.7e+00
—
2.1e+00
4.5e-01
3.9e-01
cases:17.27%
controls:15.73%
cases:17.12%
controls:7.11%
cases:4.50%
controls:0.82%
—
—
cases:7.34%
controls:1.00%
cases:13.76%
controls:9.27%
cases:25.74%
controls:18.98%
19
171
91
916
19
78
92
1019
5
9
106
1088
—
8
11
101
1086
15
101
94
988
26
187
75
798
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
-1.3e-01
9.5e-01
2.0e+00
—
-1.0e+50
4.9e-01
2.8e-01
cases:15.45%
controls:17.20%
cases:20.72%
controls:9.21%
cases:7.21%
controls:1.00%
—
—
cases:0.00%
controls:1.09%
cases:17.43%
controls:11.48%
cases:28.71%
controls:23.25%
17
187
93
900
23
101
88
996
8
11
103
1086
—
0
12
109
1085
19
125
90
964
29
229
72
756
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
-1.3e-02
4.5e-01
—
—
2.8e+00
4.6e-01
2.1e-01
cases:5.45%
controls:5.52%
cases:4.50%
controls:2.92%
—
—
—
—
cases:7.34%
controls:0.46%
cases:4.59%
controls:2.94%
cases:7.92%
controls:6.50%
6
60
104
1027
5
32
106
1065
—
—
8
5
101
1092
5
32
104
1057
8
64
93
921
FVC percent change Respiratory system
69982-7 [42868471]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.51%
—
—
—
—
—
—
8
5
93
980
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.51%
—
—
—
—
—
—
8
5
93
980
FEV1 percent change
69983-5 [42868472]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.51%
—
—
—
—
—
—
8
5
93
980
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.51%
—
—
—
—
—
—
8
5
93
980
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.51%
—
—
—
—
—
—
8
5
93
980
zopiclone; oral
N05CF01 [21604654]
5.5e-01
—
-1.0e+50
—
—
1.6e+00
1.2e+00
cases:7.27%
controls:4.32%
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:10.09%
controls:2.30%
cases:13.86%
controls:4.57%
8
47
102
1040
—
0
5
111
1092
—
—
11
25
98
1064
14
45
87
940
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
—
2.7e+00
—
—
—
—
—
—
—
cases:9.91%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
11
8
100
1089
—
—
—
—
—
Cardiodefibrillation
TFP20 [2001303224]
2.6e+00
1.0e+50
—
—
—
—
—
cases:8.18%
controls:0.64%
cases:6.31%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
9
7
101
1080
7
0
104
1097
—
—
—
—
—
General anesthesia, balanced
WX408 [2001310808]
—
—
—
—
—
2.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:5.50%
controls:0.46%
cases:6.93%
controls:1.83%
—
—
—
—
—
6
5
103
1084
7
18
94
967
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
-8.1e-02
5.8e-01
—
—
2.5e+00
3.4e-01
7.2e-02
cases:5.45%
controls:5.89%
cases:5.41%
controls:3.10%
—
—
—
—
cases:7.34%
controls:0.64%
cases:4.59%
controls:3.31%
cases:7.92%
controls:7.41%
6
64
104
1023
6
34
105
1063
—
—
8
7
101
1090
5
36
104
1053
8
73
93
912
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.71%
—
—
—
—
—
—
8
7
93
978
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.71%
—
—
—
—
—
—
8
7
93
978
FEV1
20150-9 [3024653]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.71%
—
—
—
—
—
—
8
7
93
978
Pharmacy visit
OMOP4822462 [581458]
2.8e-01
4.6e-01
6.1e-01
1.3e+00
1.2e+00
1.2e+00
1.6e+00
cases:88.18%
controls:84.91%
cases:81.08%
controls:72.93%
cases:47.75%
controls:33.18%
cases:5.41%
controls:1.55%
cases:62.39%
controls:33.18%
cases:90.83%
controls:74.29%
cases:98.02%
controls:90.86%
97
923
13
164
90
800
21
297
53
364
58
733
6
17
105
1080
68
364
41
733
99
809
10
280
99
895
2
90
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
2.4e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:0.64%
cases:7.92%
controls:2.13%
—
—
—
—
—
7
7
102
1082
8
21
93
964
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:0.46%
—
—
—
—
—
—
—
5
5
104
1084
—
perindopril; oral
C09AA04 [21601788]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:0.46%
—
—
—
—
—
—
—
5
5
104
1084
—
potassium chloride; oral
A12BA01 [21600877]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:0.91%
—
—
—
—
—
—
8
9
93
976
ECG with 12 standard connections
XF400 [2001303368]
1.2e+00
—
—
—
—
—
2.2e+00
cases:4.55%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:0.81%
5
15
105
1072
—
—
—
—
—
7
8
94
977
Sequelae of cerebral infarction
I69.3 [45533476]
—
—
—
—
1.0e+50
—
2.2e+00
—
—
—
—
—
—
—
—
cases:7.34%
controls:0.00%
—
—
cases:5.94%
controls:0.71%
—
—
—
—
8
0
101
1097
—
6
7
95
978
Emergency Room and Inpatient Visit
ERIP [262]
—
2.2e+00
—
—
—
—
3.8e-01
—
—
cases:10.81%
controls:1.37%
—
—
—
—
—
—
—
—
cases:4.95%
controls:3.45%
—
12
15
99
1082
—
—
—
—
5
34
96
951
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
3.4e-01
2.1e+00
—
—
—
—
5.1e-01
cases:5.45%
controls:3.96%
cases:7.21%
controls:0.91%
—
—
—
—
—
—
—
—
cases:6.93%
controls:4.26%
6
43
104
1044
8
10
103
1087
—
—
—
—
7
42
94
943
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
2.2e-01
9.1e-01
2.1e+00
—
—
3.4e-01
3.0e-01
cases:18.18%
controls:15.09%
cases:17.12%
controls:7.66%
cases:7.21%
controls:0.91%
—
—
—
—
cases:11.93%
controls:8.82%
cases:25.74%
controls:20.51%
20
164
90
923
19
84
92
1013
8
10
103
1087
—
—
13
96
96
993
26
202
75
783
Respiratory and circulatory monitoring
WX700 [2001310817]
1.6e+00
—
—
—
—
—
2.1e+00
cases:7.27%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
cases:9.90%
controls:1.32%
8
17
102
1070
—
—
—
—
—
10
13
91
972
Heart failure, unspecified
I50.9 [45576879]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:0.91%
—
—
—
—
—
—
7
9
94
976
Pure hypercholesterolaemia
E78.01 [2000501514]
—
2.3e+00
—
—
—
2.1e+00
—
—
—
cases:4.50%
controls:0.46%
—
—
—
—
—
—
cases:5.50%
controls:0.73%
—
—
—
5
5
106
1092
—
—
—
6
8
103
1081
—
More than one and less than three hours
ZXE10 [2001311401]
5.8e-01
—
—
—
—
2.1e+00
1.2e+00
cases:5.45%
controls:3.13%
—
—
—
—
—
—
—
—
cases:5.50%
controls:0.73%
cases:8.91%
controls:2.84%
6
34
104
1053
—
—
—
—
6
8
103
1081
9
28
92
957
Simple examination of mouth
SAA01 [2001310274]
8.8e-01
5.2e-01
—
—
—
1.2e+00
3.4e-01
cases:22.73%
controls:10.86%
cases:9.01%
controls:5.56%
—
—
—
—
—
—
cases:14.68%
controls:5.05%
cases:21.78%
controls:16.55%
25
118
85
969
10
61
101
1036
—
—
—
16
55
93
1034
22
163
79
822
Angiography of heart and/or coronary arteries
FN1AC [2001302996]
—
2.0e+00
—
1.0e+50
—
—
1.6e+00
—
—
cases:5.41%
controls:0.73%
—
—
cases:4.50%
controls:0.00%
—
—
—
—
cases:6.93%
controls:1.42%
—
6
8
105
1089
—
5
0
106
1097
—
—
7
14
94
971
Intravenous general anesthesia
WX404 [2001310807]
1.1e+00
—
—
—
—
—
1.9e+00
cases:5.45%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:1.12%
6
20
104
1067
—
—
—
—
—
7
11
94
974
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
5.2e-02
1.8e+00
2.1e+00
—
—
1.2e+00
7.4e-01
cases:4.55%
controls:4.32%
cases:12.61%
controls:2.28%
cases:4.50%
controls:0.55%
—
—
—
—
cases:7.34%
controls:2.39%
cases:8.91%
controls:4.47%
5
47
105
1040
14
25
97
1072
5
6
106
1091
—
—
8
26
101
1063
9
44
92
941
Supplier / Service Provider
OMOP5117446 [33004]
-1.4e+00
-1.1e-01
—
—
—
—
3.2e+00
cases:6.36%
controls:22.36%
cases:6.31%
controls:7.02%
—
—
—
—
—
—
—
—
cases:14.85%
controls:0.71%
7
243
103
844
7
77
104
1020
—
—
—
—
15
7
86
978
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
1.5e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:1.01%
cases:8.91%
controls:1.83%
—
—
—
—
—
5
11
104
1078
9
18
92
967
Coloscopy
UJF32 [2001305029]
—
—
—
—
—
-1.0e+50
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:7.92%
controls:1.62%
—
—
—
—
—
0
7
109
1082
8
16
93
969
Essential (primary) hypertension
I10 [45591453]
3.3e-01
1.5e+00
—
—
—
9.1e-01
2.4e-01
cases:10.91%
controls:8.10%
cases:12.61%
controls:3.19%
—
—
—
—
—
—
cases:10.09%
controls:4.32%
cases:14.85%
controls:12.08%
12
88
98
999
14
35
97
1062
—
—
—
11
47
98
1042
15
119
86
866
One hour or less
ZXE00 [2001311394]
1.2e-01
1.1e+00
—
—
—
1.4e+00
1.5e+00
cases:4.55%
controls:4.05%
cases:4.50%
controls:1.55%
—
—
—
—
—
—
cases:5.50%
controls:1.38%
cases:13.86%
controls:3.55%
5
44
105
1043
5
17
106
1080
—
—
—
6
15
103
1074
14
35
87
950
roxithromycin; oral
J01FA06 [21602974]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.89%
controls:2.94%
—
—
—
—
—
—
11
29
90
956
Emergency Medicine
93 [38004510]
6.8e-01
1.3e+00
—
—
—
4.7e-01
6.7e-01
cases:14.55%
controls:7.91%
cases:12.61%
controls:3.83%
—
—
—
—
—
—
cases:8.26%
controls:5.33%
cases:20.79%
controls:11.88%
16
86
94
1001
14
42
97
1055
—
—
—
9
58
100
1031
21
117
80
868
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
9.6e-03
1.0e+00
1.8e+00
—
-1.0e+50
4.8e-01
3.5e-01
cases:13.64%
controls:13.52%
cases:18.02%
controls:7.47%
cases:5.41%
controls:0.91%
—
—
cases:0.00%
controls:0.91%
cases:12.84%
controls:8.36%
cases:24.75%
controls:18.78%
15
147
95
940
20
82
91
1015
6
10
105
1087
—
0
10
109
1087
14
91
95
998
25
185
76
800
Cystitis, unspecified
N30.9 [45606488]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
5
110
1082
—
—
—
—
—
0
5
101
980
Parkinson disease
G20 [45538098]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.61%
0
6
110
1081
0
6
111
1091
—
—
—
0
5
109
1084
0
6
101
979
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
—
—
—
—
-1.0e+50
7.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:4.95%
controls:2.44%
—
—
—
—
—
0
7
109
1082
5
24
96
961
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
-8.1e-02
-1.0e+50
—
—
—
1.2e+00
3.7e-01
cases:5.45%
controls:5.89%
cases:0.00%
controls:1.73%
—
—
—
—
—
—
cases:4.59%
controls:1.47%
cases:6.93%
controls:4.87%
6
64
104
1023
0
19
111
1078
—
—
—
5
16
104
1073
7
48
94
937
Knee symptom/complaint
L15 [2002000639]
—
—
—
—
—
-1.0e+50
4.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:4.95%
controls:3.15%
—
—
—
—
—
0
9
109
1080
5
31
96
954
Unspecified haematuria
R31 [45553726]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
8
110
1079
—
—
—
—
—
0
7
101
978
Demanding ultrsound examination of uterus, parametrium and lower part of abdomen with speciel methods
LC2DE [2001306545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
pentoxyverine; oral, rectal
R05DB05 [21603414]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Excision of other lesion extending through all layers of skin of trunk
QBE10 [2001309853]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Written specialist consultation based on a referral from a dentist or a physician
WZC10 [2001310887]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
8
101
977
Emergency treatment
SGA01 [2001310379]
1.3e+00
—
—
—
—
—
-1.0e+50
cases:5.45%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
6
16
104
1071
—
—
—
—
—
0
14
101
971
Anxiety disorder/anxiety state
P74 [2002000868]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
5
110
1082
—
—
—
—
—
0
7
101
978
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
109
1084
—
Foreign body in skin
S15 [2002000980]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:0.00%
—
—
—
—
—
—
—
—
7
0
102
1097
—
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
14
110
1073
—
—
—
—
0
5
109
1084
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:6.42%
controls:0.00%
—
—
—
—
—
—
—
—
7
0
102
1097
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
109
1083
—
Cystocele
N81.1 [45558171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
fluticasone, combinations
R01AD58 [43534837]
3.0e-01
—
—
—
—
—
7.3e-01
cases:4.55%
controls:3.40%
—
—
—
—
—
—
—
—
—
—
cases:5.94%
controls:2.94%
5
37
105
1050
—
—
—
—
—
6
29
95
956
budesonide; inhalant
R03BA02 [21603285]
—
—
—
—
—
—
6.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:3.65%
—
—
—
—
—
—
7
36
94
949
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-1.5e-02
7.2e-01
1.5e+00
—
—
5.2e-01
1.4e-01
cases:19.09%
controls:19.32%
cases:22.52%
controls:12.40%
cases:8.11%
controls:2.01%
—
—
—
—
cases:22.94%
controls:15.06%
cases:27.72%
controls:25.08%
21
210
89
877
25
136
86
961
9
22
102
1075
—
—
25
164
84
925
28
247
73
738
Fracture of lateral malleolus
S82.6 [45569819]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Blepharitis/stye/chalazion
F72 [2002000455]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
0
13
101
972
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
—
-1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:5.48%
—
—
—
—
—
—
5
54
96
931
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.12%
—
—
—
—
—
—
5
11
96
974
Dysmenorrhoea, unspecified
N94.6 [45606522]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Spirometry study
18759-1 [3000492]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.02%
—
—
—
—
—
—
5
10
96
975
Albumin [Mass/volume] in Urine
1754-1 [3012516]
3.3e-01
—
—
—
—
—
2.5e-01
cases:4.55%
controls:3.31%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:5.48%
5
36
105
1051
—
—
—
—
—
7
54
94
931
General anaesthesia
WX402 [2001310806]
—
2.3e+00
—
—
1.0e+50
1.9e+00
1.1e+00
—
—
cases:4.50%
controls:0.46%
—
—
—
—
cases:7.34%
controls:0.00%
cases:5.50%
controls:0.83%
cases:5.94%
controls:2.13%
—
5
5
106
1092
—
—
8
0
101
1097
6
9
103
1080
6
21
95
964
Hystero-salpingography with ultrasound
LC2HE [2001306546]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Acne vulgaris
L70.0 [45581958]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
0
12
101
973
colestyramine; oral
C10AC01 [21601876]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
Sexual health counselling
SPAT1308 [2001700409]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
109
1083
—
Other and unspecified abdominal pain
R10.4 [45568113]
3.9e-01
—
—
—
—
—
1.9e-01
cases:5.45%
controls:3.77%
—
—
—
—
—
—
—
—
—
—
cases:5.94%
controls:4.97%
6
41
104
1046
—
—
—
—
—
6
49
95
936
Implementation of podiatry rehabilitation plan
SPAT1225 [2001700326]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Contraception female other
W14 [2002001214]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
6
110
1081
—
—
—
—
—
0
5
101
980
Angina pectoris
I20 [45572078]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.4e+00
1.4e+00
—
—
—
—
8.6e-01
cases:4.55%
controls:1.20%
cases:5.41%
controls:1.37%
—
—
—
—
—
—
—
—
cases:8.91%
controls:3.96%
5
13
105
1074
6
15
105
1082
—
—
—
—
9
39
92
946
promethazine, combinations
R06AD52 [21603489]
1.2e+00
-1.0e+50
—
—
—
—
—
cases:7.27%
controls:2.21%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
8
24
102
1063
0
9
111
1088
—
—
—
—
—
timolol, combinations
S01ED51 [21603705]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
0
6
110
1081
0
8
111
1089
—
—
—
0
8
109
1081
—
Glaucoma suspect
H40.0 [45567051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1080
—
—
—
—
—
—
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
0
10
110
1077
0
8
111
1089
—
—
—
—
—
Intraoral radiographic dental examination
EB1AA [2001301903]
6.2e-01
1.0e+00
—
—
—
—
-3.4e-01
cases:11.82%
controls:6.72%
cases:8.11%
controls:3.01%
—
—
—
—
—
—
—
—
cases:5.94%
controls:8.12%
13
73
97
1014
9
33
102
1064
—
—
—
—
6
80
95
905
dexamethasone and antiinfectives
S03CA01 [21605206]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.22%
0
14
110
1073
—
—
—
—
—
0
12
101
973
brompheniramine, combinations
R06AB51 [21603466]
1.1e+00
-1.0e+50
—
—
—
—
—
cases:8.18%
controls:2.76%
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
9
30
101
1057
0
11
111
1086
—
—
—
—
—
Cytology report of Urine Cyto stain
47525-1 [3049717]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Extensive health check-up of expecting family
SPAT1197 [2001700298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
—
—
—
—
—
—
0
13
101
972
Chronic hypertension
205 [2001600203]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
0
9
109
1080
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-5.3e-01
3.6e-01
1.2e+00
—
7.2e-01
1.5e-01
-2.1e-01
cases:8.18%
controls:13.16%
cases:12.61%
controls:9.12%
cases:5.41%
controls:1.73%
—
—
cases:4.59%
controls:2.28%
cases:13.76%
controls:12.12%
cases:16.83%
controls:20.00%
9
143
101
944
14
100
97
997
6
19
105
1078
—
5
25
104
1072
15
132
94
957
17
197
84
788
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.9e-01
8.2e-01
—
—
—
—
1.9e-01
cases:4.55%
controls:3.77%
cases:5.41%
controls:2.46%
—
—
—
—
—
—
—
—
cases:5.94%
controls:4.97%
5
41
105
1046
6
27
105
1070
—
—
—
—
6
49
95
936
Monitoring of normal pregnancy
SPAT1196 [2001700297]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
epinephrine; parenteral
C01CA24 [21600303]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.74%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
0
8
110
1079
0
6
111
1091
—
—
—
—
—
tretinoin; ointment
D10AD01 [21602293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
cases:0.00%
controls:1.29%
cases:0.00%
controls:2.23%
—
0
11
111
1086
—
—
—
0
14
109
1075
0
22
101
963
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.7e-01
4.0e-01
—
—
—
7.5e-01
6.0e-01
cases:13.64%
controls:9.02%
cases:8.11%
controls:5.56%
—
—
—
—
—
—
cases:12.84%
controls:6.52%
cases:21.78%
controls:13.30%
15
98
95
989
9
61
102
1036
—
—
—
14
71
95
1018
22
131
79
854
Extraction of tooth
EBA00 [2001301923]
—
—
—
—
—
—
1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:4.47%
—
—
—
—
—
—
5
44
96
941
Besnier prurigo
L20.0 [45562534]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.22%
—
—
—
—
—
—
0
12
101
973
clarithromycin; oral, parenteral
J01FA09 [21602977]
—
-1.0e+50
—
—
—
-1.0e+50
4.4e-01
—
—
cases:0.00%
controls:1.09%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
cases:4.95%
controls:3.25%
—
0
12
111
1085
—
—
—
0
15
109
1074
5
32
96
953
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
6
111
1091
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
-9.3e-02
—
—
—
—
—
6.5e-01
cases:4.55%
controls:4.97%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:3.76%
5
54
105
1033
—
—
—
—
—
7
37
94
948
Pediatric Cardiology
OMOP4821938 [45756805]
—
2.3e+00
—
—
—
—
—
—
—
cases:4.50%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
5
5
106
1092
—
—
—
—
—
Snapping jaw
K07.60 [2000502791]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
0
11
101
974
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.10%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
12
110
1075
0
5
111
1092
—
—
—
—
—
Erythrocytes [Presence] in Urine
33051-4 [3045424]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
calcium (different salts in combination); oral
A12AA20 [21600872]
—
—
-1.0e+50
—
-1.0e+50
—
2.9e-01
—
—
—
—
cases:0.00%
controls:0.91%
—
—
cases:0.00%
controls:0.91%
—
—
cases:8.91%
controls:6.80%
—
—
0
10
111
1087
—
0
10
109
1087
—
9
67
92
918
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
0
6
110
1081
0
5
111
1092
—
—
—
0
5
109
1084
—
Migraine, unspecified
G43.9 [45595943]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
10
110
1077
—
—
—
—
—
0
8
101
977
Lumbar puncture
TAB00 [2001300538]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1080
—
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
6
111
1091
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
6.7e-01
—
—
—
—
—
6.8e-01
cases:7.27%
controls:3.86%
—
—
—
—
—
—
—
—
—
—
cases:11.88%
controls:6.40%
8
42
102
1045
—
—
—
—
—
12
63
89
922
Polysomnography panel
90568-7 [1002224]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Benign paroxysmal vertigo
H81.1 [45572061]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1078
—
—
—
—
—
—
Hyperplasia of prostate
N40 [45563015]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.62%
—
—
—
—
—
—
5
16
96
969
Special examination, unspecified
Z01.9 [45576123]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
denosumab; parenteral
M05BX04 [21604169]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
5
111
1092
—
—
—
0
6
109
1083
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
109
1084
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
6
111
1091
—
—
—
0
6
109
1083
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.19%
—
—
—
—
—
—
—
0
13
109
1076
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
—
4.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.94%
controls:4.06%
—
—
—
—
—
—
6
40
95
945
oxybutynin; oral, transdermal
G04BD04 [21602637]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
109
1084
—
Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
109
1084
—
Intramural leiomyoma of uterus
D25.1 [45547585]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
9
101
976
Surveillance of (intrauterine) contraceptive device
Z30.5 [45547300]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
5
110
1082
—
—
—
—
—
0
6
101
979
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
-1.3e-01
—
—
—
—
—
-8.8e-02
cases:4.55%
controls:5.15%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:5.38%
5
56
105
1031
—
—
—
—
—
5
53
96
932
Pure hypercholesterolaemia
E78.0 [45542771]
—
—
—
—
—
-1.0e+50
7.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:4.95%
controls:2.34%
—
—
—
—
—
0
10
109
1079
5
23
96
962
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
7
111
1090
—
0
7
109
1090
—
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
-4.0e-01
3.1e-01
—
—
—
—
3.8e-01
cases:4.55%
controls:6.62%
cases:5.41%
controls:4.01%
—
—
—
—
—
—
—
—
cases:9.90%
controls:7.01%
5
72
105
1015
6
44
105
1053
—
—
—
—
10
69
91
916
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
-2.4e-01
3.4e-01
—
—
—
3.3e-01
2.8e-01
cases:5.45%
controls:6.81%
cases:6.31%
controls:4.56%
—
—
—
—
—
—
cases:8.26%
controls:6.06%
cases:13.86%
controls:10.86%
6
74
104
1013
7
50
104
1047
—
—
—
9
66
100
1023
14
107
87
878
eletriptan; oral
N02CC06 [21604381]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.91%
—
—
—
—
—
0
6
109
1083
0
9
101
976
Periodontal treatment, very brief
SDA01 [2001310326]
4.2e-01
—
—
—
—
—
4.4e-01
cases:4.55%
controls:3.04%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:3.25%
5
33
105
1054
—
—
—
—
—
5
32
96
953
Surface analgesia on skin or mucosa
WX105 [2001310765]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
0
6
111
1091
—
—
—
—
0
9
101
976
apixaban; oral
B01AF02 [43534762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
9
101
976
pimecrolimus
D11AH02 [21602339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Sentinel node biopsy
PJA12 [2001309627]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
6
110
1081
—
—
—
—
—
0
5
101
980
venlafaxine; oral
N06AX16 [21604745]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
110
1064
—
—
—
—
—
—
Gas panel - Central venous blood
97535-9 [1616796]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
-1.3e-01
—
—
—
—
—
—
cases:4.55%
controls:5.15%
—
—
—
—
—
—
—
—
—
—
—
—
5
56
105
1031
—
—
—
—
—
—
Yersinia sp identified in Stool by Organism specific culture
28549-4 [3014765]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Acute pharyngitis
J02 [45557615]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
8
101
977
insulin aspart; parenteral
A10AD05 [21600733]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
7
111
1090
—
0
7
109
1090
—
—
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
110
1077
—
—
—
—
—
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
-4.6e-01
2.0e-01
-1.0e+50
—
—
—
4.8e-01
cases:4.55%
controls:6.99%
cases:5.41%
controls:4.47%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:11.88%
controls:7.72%
5
76
105
1011
6
49
105
1048
0
5
111
1092
—
—
—
12
76
89
909
Otolaryngology
4 [38004449]
5.2e-01
—
—
—
—
—
8.8e-01
cases:14.55%
controls:9.20%
—
—
—
—
—
—
—
—
—
—
cases:18.81%
controls:8.73%
16
100
94
987
—
—
—
—
—
19
86
82
899
Chronic ischaemic heart disease
I25 [45581765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
0
8
110
1079
—
—
—
—
—
0
9
101
976
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.94%
controls:3.05%
—
—
—
—
—
—
6
30
95
955
Pain in limb
M79.6 [45587063]
—
—
—
—
—
—
5.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.91%
controls:5.28%
—
—
—
—
—
—
9
52
92
933
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
—
—
—
—
-1.0e+50
-7.6e-01
3.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:4.59%
controls:9.37%
cases:22.77%
controls:17.87%
—
—
—
—
0
7
109
1090
5
102
104
987
23
176
78
809
Extended examination of mouth
SAA03 [2001310276]
—
—
—
—
—
—
3.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.92%
controls:5.99%
—
—
—
—
—
—
8
59
93
926
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Bilateral
ZXA10 [2001311348]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.75%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
0
19
110
1068
0
6
111
1091
—
—
—
—
—
Intravenous sedation or analgesia without general anesthesia
WX006 [2001310762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
9
101
976
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
110
1076
—
—
—
—
—
—
Extensive examination of musculoskeletal system
SPAT1212 [2001700313]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
5
110
1082
—
—
—
—
—
0
5
101
980
Crystals [Presence] in Synovial fluid by Light microscopy
38458-6 [3050238]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
insulin degludec; parenteral
A10AE06 [43534747]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.46%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
5
110
1082
0
5
111
1092
—
—
—
—
0
6
101
979
Ophthalmology
18 [38004463]
3.3e-01
5.5e-01
—
—
—
3.5e-01
4.4e-01
cases:12.73%
controls:9.48%
cases:7.21%
controls:4.28%
—
—
—
—
—
—
cases:6.42%
controls:4.59%
cases:17.82%
controls:12.28%
14
103
96
984
8
47
103
1050
—
—
—
7
50
102
1039
18
121
83
864
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
—
4.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.88%
controls:8.32%
—
—
—
—
—
—
12
82
89
903
Type 2 diabetes mellitus
E11 [45571656]
—
—
—
—
—
—
2.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:3.86%
—
—
—
—
—
—
5
38
96
947
Procedure duration 90 to 119 minutes
ZXE13 [2001311404]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
3.6e-01
—
—
—
—
—
4.6e-01
cases:6.36%
controls:4.51%
—
—
—
—
—
—
—
—
—
—
cases:8.91%
controls:5.79%
7
49
103
1038
—
—
—
—
—
9
57
92
928
cefalexin; oral
J01DB01 [21602870]
1.2e-01
3.7e-02
—
—
—
5.7e-01
3.8e-01
cases:28.18%
controls:25.76%
cases:8.11%
controls:7.84%
—
—
—
—
—
—
cases:13.76%
controls:8.26%
cases:32.67%
controls:24.87%
31
280
79
807
9
86
102
1011
—
—
—
15
90
94
999
33
245
68
740
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1079
—
—
—
—
—
—
doxylamine; oral
R06AA09 [21603453]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
aciclovir; oral, parenteral
J05AB01 [21603131]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
0
9
111
1088
—
—
—
0
15
109
1074
—
Periodontal treatment by dental hygienist
SDE02 [2001310350]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.02%
—
—
—
—
—
—
5
10
96
975
carbamide
D02AE01 [21601975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Chronic rhinitis
J31.0 [45572165]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
0
7
110
1080
—
—
—
—
0
6
109
1083
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1078
—
—
—
—
—
—
nystatin
D01AA01 [21601911]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
methotrexate; oral, parenteral
L04AX03 [21603929]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.82%
cases:0.00%
controls:0.46%
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:1.93%
cases:0.00%
controls:2.23%
—
0
20
111
1077
0
5
111
1092
—
0
7
109
1090
0
21
109
1068
0
22
101
963
hydrocortisone; local oral
A01AC03 [21600036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
8
101
977
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
1.2e+00
-1.0e+50
—
—
—
—
—
cases:6.36%
controls:1.93%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
7
21
103
1066
0
9
111
1088
—
—
—
—
—
saccharomyces boulardii; oral
A07FA02 [21600670]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
2.8e-01
6.0e-01
—
—
—
7.2e-01
4.8e-01
cases:24.55%
controls:19.69%
cases:15.32%
controls:9.02%
—
—
—
—
—
—
cases:20.18%
controls:10.93%
cases:39.60%
controls:28.93%
27
214
83
873
17
99
94
998
—
—
—
22
119
87
970
40
285
61
700
Respiratory infection other
R83 [2002000951]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:3.55%
—
—
—
—
—
—
7
35
94
950
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
0
5
111
1092
—
—
—
0
5
109
1084
—
Constipation
K59.0 [45557663]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
combinations of corticosteroids
D07AB30 [21602118]
2.0e-01
—
—
—
—
—
-3.4e-01
cases:10.00%
controls:8.37%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:9.44%
11
91
99
996
—
—
—
—
—
7
93
94
892
Counselling and guidance which enhance independent living
R2130 [2001310196]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
0
10
110
1077
—
—
—
—
—
0
14
101
971
Limited function/disability (L)
L28 [2002000647]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.01%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
0
11
110
1076
0
5
111
1092
—
—
—
0
7
109
1082
—
Hypertension uncomplicated
K86 [2002000613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
9
101
976
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
0
5
111
1092
—
—
—
0
8
109
1081
—
Laboratory test
15220000 [4034850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
110
1072
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
-1.0e+50
—
—
—
-1.0e+50
2.3e-01
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:4.95%
controls:3.96%
—
0
14
111
1083
—
—
—
0
10
109
1079
5
39
96
946
Lyme disease
A69.2 [45595594]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
No procedures
SPAT1301 [2001700402]
—
—
—
—
—
-1.0e+50
5.9e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.47%
cases:7.92%
controls:4.57%
—
—
—
—
—
0
16
109
1073
8
45
93
940
hydrocortisone
C05AA01 [21601608]
1.8e-01
—
—
—
—
—
1.4e-01
cases:7.27%
controls:6.16%
—
—
—
—
—
—
—
—
—
—
cases:6.93%
controls:6.09%
8
67
102
1020
—
—
—
—
—
7
60
94
925
Acute pericoronitis
K05.22 [2000502725]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
Choriogonadotropin [Units/volume] in Serum or Plasma
19080-1 [3018171]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
0
5
111
1092
—
—
—
—
—
Angina pectoris, unspecified
I20.99 [2000502407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
oxazepam; oral
N05BA04 [21604569]
1.4e-01
—
—
—
—
8.0e-01
3.5e-01
cases:4.55%
controls:3.96%
—
—
—
—
—
—
—
—
cases:4.59%
controls:2.11%
cases:6.93%
controls:4.97%
5
43
105
1044
—
—
—
—
5
23
104
1066
7
49
94
936
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
-4.1e-01
3.6e-01
—
—
—
—
3.8e-01
cases:4.55%
controls:6.72%
cases:5.41%
controls:3.83%
—
—
—
—
—
—
—
—
cases:9.90%
controls:7.01%
5
73
105
1014
6
42
105
1055
—
—
—
—
10
69
91
916
Acute bronchitis, unspecified
J20.9 [45562445]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
6
109
1083
—
hydrocortisone and antiinfectives
S01CA03 [21603654]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Periodontitis NOS
K05.32 [2000502730]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
6
110
1081
—
—
—
—
—
0
6
101
979
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
0
10
111
1087
—
—
—
0
12
109
1077
—
chloramphenicol
D10AF03 [21602307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1078
—
—
—
—
—
—
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1080
—
—
—
—
—
—
dalteparin; parenteral
B01AB04 [21600975]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
-1.3e-01
—
—
—
—
—
-8.8e-02
cases:4.55%
controls:5.15%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:5.38%
5
56
105
1031
—
—
—
—
—
5
53
96
932
dexchlorpheniramine, combinations
R06AB52 [21603467]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
10
101
975
Risk factor NOS
A23 [2002000158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
Labour and delivery complicated by fetal heart rate anomaly
O68.0 [45548818]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Preventive oral health care, extensive
SCA03 [2001310304]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
terbutaline; inhalant
R03AC03 [21603257]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
0
7
111
1090
—
—
—
—
—
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Tinnitus, ringing/buzzing ear
H03 [2002000477]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Examination of circulation with color method
XF620 [2001303386]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:0.00%
—
—
—
—
—
—
—
5
0
104
1089
—
Monitored bed care
WX892 [2001310850]
-1.0e+50
1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:4.50%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
5
0
106
1097
—
—
—
—
—
Palpitations
R00.2 [45558446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
110
1078
—
—
—
—
—
—
Depressive episode
F32 [45595904]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1080
—
—
—
—
—
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
110
1080
—
—
—
—
—
—
Suture or treatment of traumatic wound
SPAT1149 [2001700250]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
0
9
110
1078
0
5
111
1092
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
110
1075
—
—
—
—
—
—
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
0
5
109
1084
—
desloratadine; oral
R06AX27 [21603526]
7.5e-02
—
—
—
—
—
1.7e-02
cases:4.55%
controls:4.23%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:4.87%
5
46
105
1041
—
—
—
—
—
5
48
96
937
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
110
1075
—
—
—
—
—
—
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
9
101
976
enoxaparin; parenteral
B01AB05 [21600976]
—
1.9e+00
—
—
—
—
6.3e-01
—
—
cases:4.50%
controls:0.73%
—
—
—
—
—
—
—
—
cases:5.94%
controls:3.25%
—
5
8
106
1089
—
—
—
—
6
32
95
953
Extensive initial psychiatric evaluation
IBA04 [2001304046]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Knee X-ray examination without contrast
NG1AA [2001308049]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Mouth/tongue/lip symptom/complaint
D20 [2002000319]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Cannabinoids [Presence] in Urine
3427-2 [3028300]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.32%
0
6
110
1081
—
—
—
—
—
0
13
101
972
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
0
5
111
1092
—
—
0
12
109
1077
—
sulfasalazine; oral, rectal
A07EC01 [21600663]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
0
7
109
1090
—
—
Neutrophil cytoplasmic Ab [Units/volume] in Serum
5128-4 [3001334]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
110
1081
—
—
—
—
—
—
Arthritis, unspecified
M13.9 [45567463]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.71%
—
—
—
—
—
0
6
109
1083
0
7
101
978
fluocortolone
D07AC05 [21602124]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
6
101
979
telithromycin; oral
J01FA15 [21602983]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.01%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
11
110
1076
0
6
111
1091
—
—
—
—
0
8
101
977
Blasts/Leukocytes in Blood
26446-5 [3025159]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:0.00%
controls:1.12%
0
6
110
1081
—
—
—
—
0
5
109
1084
0
11
101
974
Shoulder symptom/complaint
L08 [2002000632]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
0
8
111
1089
—
—
—
—
—
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
110
1082
—
—
—
—
—
—
Conjunctival surface anesthesia
WX100 [2001310764]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
Chlamydial infection of lower genitourinary tract
A56.0 [45585926]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
7
101
978
Examination for recruitment to armed forces
Z02.3 [45576125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1079
—
—
—
—
—
—
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
110
1079
—
—
—
—
—
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
—
—
—
—
—
—
4.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:3.25%
—
—
—
—
—
—
5
32
96
953
Chronic kidney disease
N18 [45582391]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
5
101
980
Occupational health examination
Z10.0 [45581006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
110
1077
—
—
—
—
—
—
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
0
26
110
1061
—
—
—
—
0
8
109
1081
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
87
294
5.58
25.15
8.7
4.1
1073.85
1113.39
ng/l
0.07
82
242
44
115
4.98
16.44
18.4
14.9
10.99
13.53
kpa
3.43
44
110
44
115
4.98
16.44
18.4
14.9
5.30
5.07
kpa
0.59
44
110
43
117
4.73
15.20
18.8
14.9
0.52
1.11
mmol/l
0.41
38
98
42
117
4.58
14.36
19.3
14.9
7.41
7.42
ph
0.39
27
65
59
224
3.67
12.98
6.2
3.5
591.60
133.01
ng/l
0.94
52
147
21
36
6.61
12.16
4.1
18.6
0.88
0.93
%
0.22
21
31
91
474
3.29
11.71
42.6
9.7
1.56
1.16
inr
6.41
83
390
30
83
4.26
10.14
4.2
6.1
21.50
21.79
s
0.13
24
75
24
58
4.73
9.58
3.5
12.1
—
—
—
0
0
37
129
3.47
8.95
13.4
11.0
9.67
6.67
mmol/l
1.49
37
124
44
202
2.66
6.41
5.4
2.6
13.48
13.41
umol/l
0.02
44
191
40
178
2.69
6.18
5.6
2.6
22.30
22.49
%
0.03
40
169
39
179
2.59
5.63
13.3
9.6
7.38
7.38
ph
0.11
30
103
87
575
2.20
5.33
4.4
3.3
—
—
estimate
—
0
0
36
164
2.57
5.25
3.0
1.9
—
—
—
0
0
38
179
2.50
5.17
3.0
2.3
—
—
—
0
0
56
314
2.24
5.13
4.8
5.1
—
—
—
0
0
34
162
2.42
4.47
14.9
11.2
104.56
104.51
mmol/l
0.02
34
162
8
9
9.30
4.33
2.0
3.9
0.65
0.70
nmol/l
—
8
9
13
36
3.85
3.60
11.7
13.6
74.51
62.40
%
1.62
13
36
11
26
4.48
3.58
1.2
1.2
—
—
—
0
0
62
407
1.88
3.45
5.1
3.5
28.74
30.14
ng/l
0.03
45
249
31
163
2.13
3.20
34.1
12.5
—
—
—
0
0
31
163
2.13
3.20
37.1
15.3
25.17
24.95
mmol/l
0.16
31
163
79
573
1.79
3.10
23.1
11.1
1.20
1.22
mmol/l
1.79
79
538
27
136
2.20
3.09
4.2
3.8
0.20
0.22
g/l
0.80
27
128
83
627
1.71
2.70
16.9
10.9
1.20
1.22
mmol/l
1.99
78
553
23
115
2.18
2.68
3.3
4.2
79.74
68.19
e9/l
1.31
16
81
27
455
0.51
2.66
2.3
1.9
—
—
—
0
0
5
7
7.33
2.57
2.0
17.3
140.40
173.00
mg/l
—
5
7
5
7
7.33
2.57
2.8
1.0
—
—
—
0
0
6
12
5.16
2.42
4.5
2.6
4.07
4.04
mmol/l
—
6
12
5
8
6.41
2.39
1.0
1.4
9.80
9.75
umol/l
—
5
8
8
23
3.61
2.30
2.8
4.7
—
—
—
0
0
6
13
4.76
2.29
1.7
1.2
—
—
—
0
0
8
24
3.46
2.21
2.8
1.9
—
—
—
0
0
8
24
3.46
2.21
2.8
1.9
—
—
—
0
0
8
24
3.46
2.21
2.8
1.9
—
—
—
0
0
8
24
3.46
2.21
2.8
1.9
—
—
—
0
0
140
1270
2.30
2.09
38.1
17.0
139.22
139.56
mmol/l
0.87
140
1249
140
1271
2.29
2.07
38.1
17.1
3.99
3.94
mmol/l
2.08
140
1247
15
70
2.27
2.06
10.6
10.1
0.57
0.62
%
0.23
15
70
92
750
1.57
1.96
9.0
8.5
1.71
1.99
e9/l
2.97
83
667
90
731
1.57
1.94
9.1
8.5
0.66
0.56
e9/l
1.75
80
630
55
400
1.59
1.92
4.9
3.1
—
—
—
0
0
5
12
4.27
1.84
5.2
2.6
101.40
108.00
mmol/l
—
5
12
5
12
4.27
1.84
5.2
2.6
1.17
1.19
mmol/l
—
5
12
63
479
1.54
1.79
10.1
9.6
—
—
—
0
0
41
284
1.61
1.73
4.4
3.2
1.41
1.55
mg/l
0.11
36
225
89
733
1.52
1.72
9.2
8.5
0.04
0.04
e9/l
0.13
79
629
39
269
1.61
1.67
4.2
3.5
369.66
334.29
umol/l
0.75
32
242
46
331
1.56
1.65
5.2
3.1
—
—
—
0
0
90
760
1.45
1.43
9.8
9.2
0.19
0.20
e9/l
0.01
82
670
22
136
1.72
1.42
17.5
10.4
24.42
23.81
mmol/l
0.58
22
136
6
23
2.67
1.38
8.3
2.5
1.75
1.45
mmol/l
—
6
23
6
23
2.67
1.38
11.0
18.7
10.85
10.42
%
—
6
23
5
17
3.00
1.37
1.8
1.2
—
—
—
0
0
5
17
3.00
1.37
1.2
1.8
—
—
—
0
0
0
38
0.00
1.36
0.0
4.2
—
495.56
—
0
27
0
38
0.00
1.36
0.0
4.1
—
26.35
—
0
26
14
76
1.93
1.35
17.9
16.5
1.16
1.13
mg/l
0.10
14
71
18
107
1.77
1.33
25.1
9.2
—
—
—
0
0
5
18
2.84
1.29
7.6
2.5
8.00
6.90
mmol/l
—
5
18
23
149
1.64
1.26
1.7
1.7
—
—
—
0
0
5
19
2.68
1.22
1.6
4.4
0.21
0.47
e9/l
—
5
19
11
57
2.00
1.20
1.7
2.0
—
—
—
0
0
34
245
1.50
1.20
4.3
3.0
585.07
532.35
mosm/kgh2o
0.45
29
216
6
26
2.36
1.20
2.3
4.9
22.07
35.83
%
—
6
26
5
113
0.42
1.18
3.6
1.6
—
—
—
0
0
5
114
0.42
1.18
4.0
1.6
—
—
—
0
0
94
818
1.39
1.15
11.2
12.5
4.29
3.85
e9/l
1.06
82
704
19
120
1.67
1.15
1.4
1.4
132.04
279.85
u/ml
0.52
19
112
55
438
1.40
1.15
9.5
9.0
—
—
—
0
0
21
137
1.62
1.13
8.4
3.3
9.20
10.07
g/l
0.45
21
127
5
108
0.44
1.05
3.6
1.6
—
—
—
0
0
46
360
1.40
1.05
4.9
4.3
7.39
7.39
ph
0.03
36
258
5
22
2.31
1.04
12.8
3.8
—
—
—
0
0
0
32
0.00
0.96
0.0
4.6
—
—
—
0
0
6
29
2.11
0.90
1.8
2.2
19.83
33.07
ng/l
—
6
29
6
29
2.11
0.90
2.5
2.4
4.83
133.63
u/ml
—
6
29
6
30
2.04
0.88
1.2
2.7
11.32
6.77
umol/l
—
6
22
16
233
0.65
0.85
1.8
1.3
5.70
6.05
u/ml
—
7
92
126
1179
1.40
0.80
37.1
19.2
13.89
13.36
%
3.62
126
1163
0
25
0.00
0.80
0.0
1.2
—
—
—
0
0
39
311
1.34
0.79
4.7
4.1
16.64
8.76
mg/mmol
0.21
29
197
5
24
2.12
0.75
1.6
1.5
—
—
—
0
0
5
26
1.95
0.71
1.6
4.2
3.28
4.21
e9/l
—
5
26
5
27
1.88
0.69
3.6
4.3
4.96
4.83
kpa
—
5
27
5
27
1.88
0.69
10.8
4.4
19.22
15.00
mu/l
—
5
27
5
27
1.88
0.69
3.6
4.3
8.58
9.11
kpa
—
5
27
13
86
1.56
0.68
2.1
2.0
—
—
—
0
0
50
427
1.25
0.61
1.5
1.6
—
—
—
0
0
0
22
0.00
0.60
0.0
6.3
—
—
—
0
0
6
36
1.69
0.57
1.3
1.4
—
—
—
0
0
140
1350
1.47
0.57
32.9
16.9
73.22
70.30
umol/l
0.71
140
1338
142
1455
0.63
0.57
42.9
22.4
133.38
135.88
g/l
1.08
142
1446
6
37
1.65
0.56
3.3
3.5
7.41
7.42
ph
—
6
37
142
1454
0.64
0.54
42.1
22.1
30.00
29.92
pg
0.21
142
1446
142
1454
0.64
0.54
47.6
22.9
40.08
40.54
%
0.47
142
1446
41
347
1.25
0.53
4.3
2.9
—
—
—
0
0
18
233
0.74
0.52
1.4
1.8
—
—
—
0
0
142
1453
0.65
0.51
42.2
22.1
90.24
89.40
fl
1.25
142
1445
31
369
0.80
0.48
3.7
3.9
0.00
0.00
estimate
-0.00
12
133
53
467
1.21
0.47
2.6
1.9
102.48
96.14
pmol/l
0.58
37
229
34
399
0.81
0.46
2.0
2.0
—
—
—
0
0
36
309
1.22
0.42
4.2
3.5
32.17
58.01
mg/l
0.39
29
205
0
15
0.00
0.41
0.0
1.7
—
33.30
—
0
10
0
15
0.00
0.41
0.0
13.0
—
890.27
—
0
15
0
15
0.00
0.41
0.0
18.9
—
1507.47
—
0
15
0
16
0.00
0.41
0.0
5.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
178.97
—
0
17
0
19
0.00
0.39
0.0
3.0
—
57.87
—
0
19
0
19
0.00
0.39
0.0
2.0
—
—
—
0
0
14
107
1.34
0.39
3.1
4.6
1.07
0.82
%
—
7
37
6
88
0.67
0.34
1.3
1.0
—
—
—
0
0
65
703
0.87
0.34
4.3
3.7
0.00
0.00
estimate
-0.00
11
133
6
46
1.32
0.33
1.5
2.9
57.72
58.47
%
—
6
46
24
281
0.83
0.32
1.8
1.9
—
—
—
0
0
7
53
1.34
0.31
5.1
5.8
36.99
36.95
°c
—
7
53
7
55
1.29
0.30
1.3
1.2
—
—
—
0
0
7
56
1.26
0.30
2.0
1.3
—
—
—
0
0
12
94
1.30
0.29
2.3
4.8
0.42
0.71
%
—
6
29
5
73
0.67
0.26
1.0
1.8
195.20
337.85
mu/l
—
5
67
18
151
1.22
0.26
1.5
1.4
—
—
—
0
0
70
656
1.12
0.26
15.9
12.8
0.00
0.00
e9/l
0.80
56
518
6
82
0.72
0.25
3.3
2.7
4.68
5.40
u/l
—
6
56
65
692
0.89
0.24
4.2
3.6
0.00
0.00
estimate
-0.00
13
139
66
702
0.89
0.24
4.2
3.6
0.00
0.00
estimate
-0.00
12
139
46
422
1.13
0.24
1.7
1.6
2.28
2.18
g/l
0.15
29
237
7
91
0.76
0.23
2.9
4.4
2.24
10.18
ug/l
—
7
67
13
156
0.82
0.22
1.4
1.2
—
—
—
0
0
11
89
1.25
0.21
1.1
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
66.60
—
0
10
0
10
0.00
0.21
0.0
1.1
—
214.00
—
0
10
42
386
1.12
0.21
3.6
3.2
1.09
0.24
e6/l
0.98
32
280
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
167.42
—
0
12
48
516
0.90
0.21
4.5
3.4
0.15
0.01
estimate
0.44
13
117
33
299
1.13
0.21
3.3
3.1
7.31
6.72
e6/l
0.08
28
276
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
4.9
—
3.11
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
12
99
1.23
0.20
3.2
4.8
0.00
0.20
%
—
5
30
37
341
1.11
0.18
3.5
4.8
—
—
—
0
0
47
439
1.10
0.18
4.0
3.5
10.27
45.57
e6/l
1.61
40
331
40
371
1.11
0.17
3.4
3.2
—
—
estimate
—
0
0
30
326
0.90
0.16
3.5
3.4
1.02
1.02
kg/l
0.30
17
210
48
509
0.92
0.16
2.8
2.7
—
—
—
0
0
9
79
1.15
0.15
6.2
6.0
7.34
7.35
ph
—
9
61
9
80
1.13
0.15
1.1
1.2
—
—
—
0
0
53
502
1.09
0.15
4.6
4.4
16.63
31.35
e6/l
1.13
43
345
29
314
0.91
0.14
1.8
1.7
—
—
—
0
0
8
97
0.82
0.14
2.6
1.7
—
—
—
0
0
8
100
0.79
0.14
3.0
1.5
—
—
—
0
0
116
1135
1.09
0.14
5.1
4.2
5.81
5.72
mmol/l
0.32
110
1053
9
109
0.81
0.13
3.0
2.3
11.90
20.49
iu/l
—
9
79
42
444
0.93
0.12
1.8
1.6
0.89
2.06
u/ml
—
10
101
17
153
1.13
0.11
1.5
1.3
—
—
—
0
0
16
175
0.90
0.09
1.3
1.3
—
—
—
0
0
6
56
1.07
0.09
1.3
1.4
—
—
—
0
0
6
57
1.05
0.08
3.0
1.8
181.00
164.76
u/ml
—
6
29
9
100
0.89
0.06
3.9
3.7
—
—
—
0
0
112
1107
1.04
0.05
6.7
5.3
38.74
37.99
mmol/mol
0.41
107
1051
11
120
0.91
0.05
1.2
1.4
—
—
—
0
0
13
120
1.09
0.05
1.6
1.3
180.40
148.45
u/ml
—
5
39
50
512
0.97
0.04
2.0
1.9
1.31
1.36
mmol/l
0.19
45
450
38
390
0.97
0.03
4.7
3.0
0.15
0.00
estimate
0.47
13
111
133
1322
1.05
0.02
30.2
14.8
22.03
21.60
mg/l
0.07
120
1056
23
238
0.96
0.02
1.9
1.6
—
—
—
0
0
12
114
1.06
0.01
2.9
2.3
10.18
13.11
nmol/l
0.61
12
108
136
1354
1.04
0.00
28.2
11.4
—
—
—
0
0
14
144
0.97
0.00
1.6
1.5
—
—
—
0
0
22
216
1.02
0.00
3.7
3.0
4.86
2.81
e6/l
0.19
13
107
57
572
0.99
0.00
4.0
3.3
6.42
6.23
ph
0.63
31
312
110
1103
0.99
0.00
4.5
3.8
1.19
1.26
mmol/l
0.58
105
1027
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
2.01
—
0
6
0
6
0.00
0.00
0.0
10.3
—
—
—
0
0
8
84
0.95
-0.00
5.4
4.2
1.25
1.23
mmol/l
—
8
71
0
5
0.00
-0.00
0.0
6.0
—
8.00
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
-0.00
1.2
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
7.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
2.18
—
0
5
6
62
0.97
-0.00
2.3
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
158.67
—
0
7
0
5
0.00
-0.00
0.0
3.0
—
28.40
—
0
5
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
35.6
—
0.44
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint Q17_AVSD and mortality.

Females

Parameter HR [95% CI] p-value
Q17_AVSD 4.493 [3.29, 6.14] < 0.001
Birth year 0.994 [0.99, 1.0] 0.172

During the follow-up period (1.1.1998 — 31.12.2019), 95 out of 688 females with Q17_AVSD died.

Males

Parameter HR [95% CI] p-value
Q17_AVSD 4.775 [3.37, 6.76] < 0.001
Birth year 0.985 [0.98, 0.99] 0.003

During the follow-up period (1.1.1998 — 31.12.2019), 82 out of 494 males with Q17_AVSD died.

Mortality risk

Mortality risk for people of age

years, who have Q17_AVSD.

N-year risk Females Males
1 0.368% 0.978%
5 2.179% 6.07%
10 6.341% 13.382%
15 11.155% 23.091%
20 19.056% 36.039%

Relationships between endpoints

↥

Index endpoint: Q17_AVSD – Atrioventricular septal defect

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data